pacifica: pacritinib versus physician’s choice in myelofibrosis
Published 3 years ago • 126 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
2:18
results of persist-1 & persist-2 studies of pacritinib vs best alternative therapy in myelofibrosis
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
1:28
indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
-
1:59
pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia
-
4:12
pacritinib for patients with mf across the cytopenic spectrum
-
1:21
pacifica: phase iii study of pacritinib vs bat in patients with mf and severe thrombocytopenia
-
0:54
study design for persist-2 and other upcoming trials of pacritinib
-
5:24
biopacific materials innovation platform - micro electron diffraction
-
13:58
myelofibrosis disease overview and treatment options
-
4:36
being marilyn…with myelofibrosis—an mf journey
-
2:03
results of the phase 3 persist-1 trial of pacritinib in myelofibrosis
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
4:48
an insight into the management of cytopenias in mf
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
1:45
managing cardiovascular risks in patients with chip and mpns: insights from a cardiologist
-
3:33
manifest: pelabresib (cpi-0610) shows promise in myelofibrosis
-
3:06
manifest study of pelabresib (cpi-0610) in myelofibrosis
-
1:27
bet inhibitor pelabresib (cpi-0610) and ruxolitinib for myelofibrosis
-
4:25
update on momelotinib for myelofibrosis
-
2:21
avapritinib updates in advanced systemic mastocytosis: explorer and pioneer
-
1:28
clonal hematopoiesis increases the risk of progression in patients with asymptomatic wm